These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9816320)

  • 1. Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
    Preisler HD; Kotelnikov VM; LaFollette S; Taylor S; Mundle S; Wood N; Coon JS; Hutchinson J; Panje W; Caldarelli DD; Griem K
    Clin Cancer Res; 1996 Sep; 2(9):1453-60. PubMed ID: 9816320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis.
    Kotelnikov VM; Coon JS; Mundle S; Kelanic S; LaFollette S; Taylor S IV; Hutchinson J; Panje W; Caldarelli DD; Preisler HD
    Clin Cancer Res; 1997 Jan; 3(1):95-101. PubMed ID: 9815543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation of epithelia of noninvolved mucosa in patients with head and neck cancer.
    Kotelnikov VM; Coon JS; Taylor S; Hutchinson J; Panje W; Caldareill DD; LaFollette S; Preisler HD
    Head Neck; 1996; 18(6):522-8. PubMed ID: 8902565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell kinetics of head and neck cancers.
    Kotelnikov VM; Coon JS IV; Haleem A; Taylor S IV; Hutchinson J; Panje W; Caldarelli DD; Griem K; Preisler HD
    Clin Cancer Res; 1995 May; 1(5):527-37. PubMed ID: 9816012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A; Li Y; Forastiere A
    Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
    Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
    Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
    Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
    Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues.
    Kotelnikov V; Cass L; Coon JS; Spaulding D; Preisler HD
    Clin Cancer Res; 1997 May; 3(5):669-73. PubMed ID: 9815735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
    Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
    J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
    Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
    Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
    Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
    Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
    Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
    Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
    Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
    Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.